SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
DURHAM, N.C., May 02, 2017 -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 3258363. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
About Chimerix
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: [email protected] or Will O’Connor Stern Investor Relations [email protected] 212-362-1200 Media: Becky Vonsiatsky W2O Group [email protected] 413-478-2003
